Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2007

FR Doc E7-1402 [Federal Register: January 30, 2007 (Volume 72, Number 19)] [Notices] [Page 4298] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr30ja07-114]

[[Page 4298]]


Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 17, 2006, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug  Schedule
Codeine-N-oxide (9053)  I
Difenoxin (9168)  I
Dihydromorphine (9145)  I
Morphine-N-oxide (9307)  I
Norlevorphanol (9634)  I
Normorphine (9313)  I
Tetrahydrocannabinols (7370)  I
Nabilone (7379)  II
Alfentanil (9737)  II
Amphetamine (1100)  II
Ecgonine (9180)  II
Codeine (9050)  II
Dextropropoxyphene, bulk (9273)  II
Dihydrocodeine (9120)  II
Diphenoxylate (9170)  II
Diprenorphine (9058)  II
Etorphine HCL (9059)  II
Fentanyl (9801)  II
Hydrocodone (9193)  II
Hydromorphone (9150)  II
Levo-alphacetylmethadol (9648)  II
Levorphanol (9220)  II
Meperidine (9230)  II
Methadone (9250)  II
Methadone intermediate (9254)  II
Methamphetamine (1105)  II
Methylphenidate (1724)  II
Metopon (9260)  II
Morphine (9300)  II
Opium extracts (9610)  II
Opium fluid extract (9620)  II
Opium tincture (9630)  II
Opium, granulated (9640)  II
Opium, powdered (9639)  II
Oxycodone (9143)  II
Oxymorphone (9652)  II
Noroxymorphone (9668)  II
Phenazocine (9715)  II
Alfentanil (9737)  II
Remifentanil (9739)  II
Sufentanil (9740)  II
Thebaine (9333)  II

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than April 2, 2007.

Dated: January 23, 2007.

Joseph T. Rannazzisi, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7-1402 Filed 1-29-07; 8:45 am]


NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility